SuperworthRevelation Biosciences REVB
- Market cap
- $2.2M
- PE
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- n/m
- not a meaningful number
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- n/m
- not a meaningful number
- Net margin
- n/m
- not a meaningful number
- Free cash flow yield
- n/m
- not a meaningful number
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D | $1.7M+333% | $1.1M+212% | $717.6K+37% | $1.4M+53% | $831K−50% | $605.5K−43% | $858.8K+20% | $1.3M−6% | $922.9K+11% | $964.2K+59% | $1.4M+60% | $1.9M+46% |
| SG&A | $1.1M+38% | $1.3M+44% | $1.2M+8% | $1.1M+10% | $965.7K−14% | $1.1M−9% | $1.2M+4% | $1.1M+1% | $1M+6% | $1.6M+40% | $1.7M+39% | $1.7M+53% |
| −$2.8M+132% | −$2.3M+91% | −$1.9M+17% | −$2.5M+31% | −$1.8M−35% | −$1.8M−25% | −$2.1M+10% | −$2.5M−2% | −$1.9M+8% | −$2.6M+47% | −$3.1M+48% | −$3.7M+49% | |
| Net income | −$2.6M+125% | −$2.2M+82% | −$2.7M | −$8.4M+479% | −$2.2M−15% | −$1.7M−22% | −$2.1M−24% | −$2.4M−71% | −$1.9M−15% | −$2.5M+46% | −$3M+47% | −$3.3M+36% |
| −$13359.36−83% | −$11311.44−36% | −$3307.08 | −$6895.56−12% | −$1124.20−92% | −$418.32−96% | −$177.38−95% | −$196.28−97% | −$49.56−96% | n/a | −$18.97−89% | −$6.09−97% | |
| 197+1197% | 195+185% | 811+556% | 1.2K+558% | 2K+913% | 4.1K+2017% | 11.6K+1326% | 28.7K+2256% | 94.5K+4637% | n/a | 458.2K+3863% | 547.1K+1808% |
EPS, diluted: 4 periods, Q4 FY20 to Q4 FY24: quarter's net income to common over its shares, to the cent.
Diluted shares: Q4 FY20: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q4 FY22: a loss quarter: its basic count, share-days: the 12-month average over 365 days less the 9-month over 273, the two on one basis (x7.426). Q4 FY23: a loss quarter: its basic count, share-days: the 12-month average over 365 days less the 9-month over 273, the two on one basis (x16). Q4 FY24: a loss quarter: its basic count, share-days: the 12-month average over 366 days less the 9-month over 274, the two on one basis (x16).
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Healthcare nearest Revelation Biosciences' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| REVBRevelation Biosciences | $2.2M | n/m | n/a | n/m | n/m | n/m | |
| OXBROXBRIDGE RE HOLDINGS | $7.7M | 47.5× | 9.6× | 2.8× | +40% | 4.7% | |
| EDUCEducational Development | $8.7M | 5.4× | 11.3× | 0.4× | −32% | 8.6% | |
| GTIMGood Times Restaurants | $13.6M | 6.1× | 13.6× | 0.1× | −6% | 1.7% | |
| MDRRMedalist Diversified | $15.4M | 2.5× | 3.0× | 1.6× | −1% | 80.2% | |
| BCGBinah Capital | $18.2M | 6.7× | 20.8× | 0.1× | +8% | 2.2% | |
| VIPVulcan Infrastructure & Power | $19.6M | 17.9× | 24.4× | 0.4× | −14% | 1.0% | |
| MXCMexco Energy | $20.5M | 13.4× | 13.3× | 3.0× | −9% | 23.3% | |
| CKXCKX Lands | $21.5M | 7.4× | 32.6× | 31.0× | −17% | n/m | |
| Peer median | $16.8M | 7.0× | 13.4× | 1.0× | −7% | 4.7% |
More on Revelation Biosciences
Each number over time
Its groups
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .